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Footnotes and Abbreviations 
99mTc: 99mTechnetium 
BM-MSCs: bone marrow-derived mesenchymal stromal cells 
hUC-MSCs: human umbilical cord Wharton's jelly-derived mesenchymal stromal cells 
ICH: intracerebral hemorrhage 
mICH: moderate intracerebral hemorrhage 
MSC: mesenchymal stromal cell 






























































































































































































































































































Intracerebral hemorrhage (ICH) is as a life-threatening condition that can occur in young 
adults, often causing long-term disability. Recent preclinical data suggests mesenchymal 
stromal cell (MSC)-based therapies as promising options to minimize brain damage after 
ICH. However, therapeutic evidence and mechanistic insights are still limited, particularly 
when compared to other disorders such as ischemic stroke. Herein, we employed a model 
of collagenase-induced ICH in young adult rats to investigate the potential therapeutic 
effects of an intravenous injection of human umbilical cord Wharton's jelly-derived MSCs 
(hUC-MSCs). Two doses of collagenase were used to cause moderate or severe 
hemorrhages. Magnetic resonance imaging showed that animals treated with hUC-MSCs 
after moderate ICH had smaller residual hematoma volumes than vehicle-treated rats, 
whereas the cell therapy failed to decrease the hematoma volume in animals with a severe 
ICH. Functional assessments (rotarod and elevated body swing tests) were performed for 
up to 21 days after ICH. Enduring neurological impairments were seen only in animals 
subjected to severe ICH, but the cell therapy did not induce statistically significant 
improvements in the functional recovery. The biodistribution of Technetium-99m-labeled 
hUC-MSCs was also evaluated, showing that most cells were found in organs such as the 
spleen and lungs 24 h after transplantation. Nevertheless, it was possible to detect a weak 
signal in the brain, which was higher in the ipsilateral hemisphere of rats subjected to a 
severe ICH. These data indicate that hUC-MSCs have moderately beneficial effects in cases 
of less severe brain hemorrhages in rats by decreasing the residual hematoma volume, and 
that optimization of the therapy is still necessary. 
Keywords: cell therapy; stem cells; mesenchymal stromal cells; Wharton's jelly; 





























































































































































































































































































The absolute number of stroke survivors and of people living with disability following 
stroke has increased in the last decades [1]. It has been estimated that the global lifetime 
risk of stroke among adults aged 25 years or older is 18.3% for ischemic stroke and 8.2% 
for hemorrhagic stroke [2]. Although the likelihood of having a hemorrhagic stroke 
increases with ageing, recent research has begun to draw attention to nontraumatic 
intracerebral hemorrhage (ICH) in young and middle-aged adults (<50 years of age), due to 
its particularities and major socioeconomic consequences. ICH in this group has an annual 
incidence of 4.9 per 100,000 individuals and is more often associated with a poor long-
term functional outcome than ischemic stroke [3-5]. For instance, Koivunen and colleagues 
reported an unfavorable outcome in 48.9% of the survivors of ICH at a young age [6]. 
While current therapeutic options for ischemic stroke are focused on the restoration of 
cerebral blood flow and protection of the ischemic penumbra [7], treatment of ICH is 
mainly based on supportive care, management of coagulopathy and blood pressure 
control, with surgical approaches for hematoma evacuation being reserved for selected 
cases [8]. The identification of mechanisms of secondary brain injury following ICH, such as 
inflammation and the toxicity of blood products, has led to a large number of preclinical 
studies focused on immunomodulation and hematoma resolution [9-11]. Recent clinical 
trials, however, have failed to recapitulate the benefit of several pharmacological and 
surgical therapies in patients with ICH, although only a few young patients have been 
included in these trials [4,9]. 
It has also been suggested that mesenchymal stromal cell (MSC)-based therapies would 
represent promising strategies for treating ICH patients, by targeting multiple mechanisms 
of brain injury [12,13]. Treatments based on human or murine bone marrow-derived 
mesenchymal stromal cells (BM-MSCs), for instance, have been shown to have anti-
inflammatory and neuroprotective effects in models of ICH [14]. Compared to BM-MSCs, 
however, human umbilical cord Wharton's jelly-derived mesenchymal stromal cells (hUC-
MSCs) offer the advantages of being easily obtained from a routinely discarded tissue 




























































































































































































































































































greater proliferative activity in vitro [15]. Moreover, BM-MSCs and hUC-MSCs have 
distinctive transcriptional profiles [16,17] and secretomes [18-20]. Although systemic hUC-
MSC administration has been widely used in preclinical and clinical studies for other 
conditions, including ischemic stroke [21], the preclinical efficacy of hUC-MSCs in ICH has 
so far only been assessed in a few studies. Most of these studies used the intracerebral 
route for cell administration [22-25], which is a complex and invasive procedure not 
entirely free of complications [26]. In addition, it is not known whether ICH severity affects 
hUC-MSC-based treatments. In this study, we used collagenase-induced models of 
moderate and severe ICH (mICH and sICH, respectively) to address these translationally 
relevant points. 
Materials and Methods 
Animals 
Male Wistar rats aged 7–10 weeks and weighing 335–435 g (mean age: 55 ± 7 days) were 
used in this study. The emergence of adult-type behaviors was reported to occur around 
this age in rodents (postnatal day 60 in rodents, corresponding to >20 years in humans) 
[27]. All procedures were approved and conducted in accordance with the Animal Care 
and Use Committee at the Universidade Federal do Rio de Janeiro (protocol number 
111/14). All animals received humane care in compliance with the “Principles of 
Laboratory Animal Care” formulated by the National Society for Medical Research and the 
U.S. National Academy of Sciences Guide for the Care and Use of Laboratory Animals.  
Intracerebral hemorrhage model 
In this study, we used the model of collagenase-induced spontaneous ICH developed by 
Rosenberg et al. [28], with minor modifications. For analgesia, rats were given an 
intraperitoneal injection of tramadol (12.5 mg/kg) 15 min prior to anesthesia. The animals 
were anesthetized via an intraperitoneal injection of xylazine hydrochloride (15 mg/kg) 
and ketamine hydrochloride (100 mg/kg), and were then placed in a stereotaxic apparatus. 
An intradermal injection of lidocaine (5 mg/kg) was administered before an incision was 
made along the longitudinal midline of the scalp [29]. Bregma was located, and a hole 




























































































































































































































































































gauge needle attached to a 10-μL syringe (Hamilton) into the left striatum (3 mm lateral to 
midline, 0.2 mm posterior to bregma, 6 mm below the surface of the skull) [30,31]. 2 μL of 
sterile saline containing 0.1 U or 0.25 U of bacterial collagenase IV-S (Sigma-Aldrich) or the 
same volume of the vehicle (sham group) was then injected at a constant rate of 0.25 
μL/min using a microinfusion pump (Harvard Apparatus) [31]. After infusion, the needle 
was left in place for 10 min, and then withdrawn slowly to prevent backflow. The burr hole 
was sealed with dental cement, the skin was sutured, and rats were placed in clean cages 
with free access to food and water. Normothermia was maintained during and after 
surgery using a heating pad and heating lamps. 
hUC-MSC isolation and culture 
Umbilical cords were collected from term deliveries after the informed consent forms 
were signed by the mothers. This procedure was approved by the Institutional Ethics 
Committee of the Universidade Federal do Rio de Janeiro. hUC-MSCs were isolated as 
previously described [32]. Briefly, cords were cut into smaller pieces, and dissected for the 
removal of the arteries and the vein, leaving only the Wharton's jelly. The remaining tissue 
was then digested with collagenase II (200 U/mL; Gibco) diluted in phosphate-buffered 
saline (PBS) for 16 h at 37°C under slow stirring. The digested material was washed in PBS 
and plated in Dulbecco's Modified Eagle’s Medium: Nutrient Mixture F-12 (DMEM/F12; 
Invitrogen) culture medium supplemented with 15% fetal bovine serum (FBS; Invitrogen) 
and 1% penicillin/streptomycin (Gibco). Cells were kept at 37°C in an incubator with 5% 
CO2. After reaching confluence, cells were enzymatically dissociated by incubation with a 
trypsin solution (0.25% trypsin + 1 mM EDTA; Gibco) for 5 min. For cryopreservation, cells 
at passage number 3 to 5 were resuspended in FBS containing 10% dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich), and frozen in liquid nitrogen. We used hUC-MSCs from a single 
donor to reduce donor-related variability. The MSC identity was confirmed by evaluating 
the expression of cell-surface markers by flow cytometry, as demonstrated in our previous 
study [32], as well as by assessing their capacity to differentiate into cells of the mesoderm 






























































































































































































































































































On the day of injection, vials containing hUC-MSCs were defrosted. Cells were then 
centrifuged at 300 × g for 5 min, washed 3x with PBS containing Pulmozyme (recombinant 
human DNase I; 0.6 µl/mL; Roche), and resuspended in PBS + Pulmozyme. A small fraction 
of cells was stained with trypan blue to assess cell viability and concentration. Animals 
were randomly allocated to receive either 3 × 106 hUC-MSCs (suspended in 0.5 mL of PBS + 
Pulmozyme) or the same volume of the vehicle via the tail vein, infused over 2–3 min, 24 h 
after ICH. This dosage was chosen based on the doses used in studies that investigated the 
effects of bone marrow-derived MSCs in models of ICH [14]. Pulmozyme was used to avoid 
MSC aggregation, as described previously [33]. Sham-operated animals received an 
intravenous injection of the same volume of the vehicle 24 h after the surgical procedure. 
Rotarod performance test 
The rotarod test was employed to assess motor coordination and balance. Animals were 
pretested by an examiner blinded to treatment allocation 2 days before ICH induction, and 
then tested on days 3, 7, 14, and 20 after ICH. The animals were placed in a neutral 
position and the rod was set to accelerate from 8 to 37 rpm in 320 s. Rats were subjected 
to three trials per session, with an interval of 5 min between each trial. The time spent on 
the rotarod (i.e., the latency to fall) was recorded in each trial. Rats remaining on the 
rotarod for more than 420 s were removed and their latency to fall was recorded as 420 s. 
For statistical analysis, the best trial (i.e., the longest time spent on the rotarod) was 
chosen for each animal. 
Elevated body swing test 
The elevated body swing test was performed by an examiner blinded to treatment 
allocation for the measurement of asymmetrical motor behavior, as described by 
Borlongan & Sanberg [34]. Animals were pretested 1 day before ICH induction, and then 
tested on days 1, 8, 15, and 21 after ICH. Briefly, animals were suspended in the air by the 
tail, and the direction of body swing (“a >10° bending of the upper body out of the vertical 




























































































































































































































































































intervals between the blocks. The percentage of right-side swings in 20 trials was 
quantified. 
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) was used to measure the volume of the residual 
hematoma and hemispheric atrophy. On day 22 after ICH, rats were deeply anesthetized 
via an intraperitoneal injection of a mixture of xylazine hydrochloride (15 mg/kg) and 
ketamine hydrochloride (100 mg/kg), and then transcardially perfused with ice-cold 0.9% 
saline, followed by 4% paraformaldehyde (PFA) in phosphate buffer, pH 7.4. The heads 
were kept in 4% PFA until image acquisition. 
For the model of mICH, MRI was carried out in a 7.0 Tesla Magnetic Resonance System (7 
T/400 horizontal Varian scanner; Agilent Technologies) at the Centro Nacional de Biologia 
Estrutural e Bioimagem (CENABIO). T1- and T2*-weighted 3D sequences were acquired 
using the same geometric parameters: FOV = 32 x 32 x 32 mm with a matrix of 128 x 128 x 
128, resulting in an isotropic spatial resolution of 250 μm. The images were reconstructed 
using zero filling for a 256 x 256 x 256 matrix. T1-weighted images were acquired with a 
gradient echo (GRE) sequence with the following parameters: TE / TR = 5 / 50 ms, flip angle 
= 20 degrees, bandwidth = 15 kHz. T2*-weighted images were acquired with GRE sequence 
with the following parameters: TE / TR = 15 / 500 ms, flip angle = 20 degrees, bandwidth = 
15 kHz. The residual hematoma volume and the volume of cerebral hemispheres were 
calculated using the OsiriX software (OsiriX 4.0; Pixmeo SARL) by an examiner blinded to 
treatment allocation. To evaluate the residual hematoma volume, the region of interest 
(ROI) was marked around the residual hematoma in all coronal sections where it was 
visible. The volume of cerebral hemispheres was calculated by measuring the surface area 
of each hemisphere in 40 coronal sections starting from the following stereotaxic 
coordinate: anterior/posterior (AP): +2.2 mm from bregma, which spanned the area where 
the hematoma was present in all animals. 
For the model of sICH, MRI was carried out in a 2.0 Tesla Magnetic Resonance System 
composed of an Oxford Instruments 85310HR Magnet (Oxford Instruments) and Bruker 




























































































































































































































































































de São Paulo. A locally developed solenoid coil was used as a transmission and reception 
coil. T1-, T2- and T2*-weighted 3D sequences were acquired using the same geometric 
parameters: FOV = 32 x 32 x 32 mm with a matrix of 128 x 128 x 128, resulting in an 
isotropic spatial resolution of 250 μm. The images were reconstructed using zero filling for 
a 256 x 256 x 256 matrix. T1-weighted images were acquired with a gradient echo (GRE) 
sequence with the following parameters: TE / TR = 15 / 3.5 ms, flip angle = 30 degrees, 
bandwidth = 15 kHz. T2-weighted images were acquired using a PSIF sequence with the 
following parameters: TR / TE: 24 / 7 ms, flip angle = 60 degrees, bandwidth = 15 kHz. 
Finally, T2*-weighted images were acquired with GRE sequence with the following 
parameters: TE / TR = 20 / 10.5 ms, flip angle = 5 degrees, bandwidth = 15 kHz. The 
residual hematoma volume and the volume of cerebral hemispheres were calculated using 
the Medical Image Processing, Analysis, and Visualization application (MIPAV 8.0.2; 
National Institute of Health) by an examiner blinded to treatment allocation. To evaluate 
the residual hematoma volume, the region of interest (ROI) was marked around the 
residual hematoma in all coronal sections where it was visible. The volume of cerebral 
hemispheres was calculated by measuring the surface area of each hemisphere in 50 
coronal sections starting from the following stereotaxic coordinate: anterior/posterior 
(AP): +2.2 mm from bregma, which spanned the area where the hematoma was present in 
all animals. 
Experimental design 
Sham group: 10 rats were randomly allocated to the sham group. Animals from the sham 
group received an intrastriatal injection of saline, followed by an intravenous injection of 
saline 24 h later. No deaths occurred in the sham group during the 22-day follow-up 
period. Behavioral assessments were performed as described above in all animals (Figure 
1). 
mICH: 24 rats received an intrastriatal injection of 0.1 U collagenase into the left striatum 
to induce a moderate ICH. 4 rats died within the first 24 h following the surgery and the 
remaining 20 animals were randomly selected to receive either a single intravenous 
injection of 3 × 106 hUC-MSCs (mICH + hUC-MSC group; n = 10) or of the vehicle (mICH + 




























































































































































































































































































which no deaths occurred. Behavioral assessments were performed as described above in 
all animals, but 1 animal from the mICH + Vehicle and 2 animals from the mICH + hUC-MSC 
group were excluded from the rotarod analysis due to a technical problem. 1 animal from 
the mICH + Vehicle group was excluded from the study due to the absence of a visible 
hematoma on MRI. 
sICH: 47 rats received an intrastriatal injection of 0.25 U collagenase in the left striatum to 
model a sICH. 19 rats died within the first 24 h following the surgery and the remaining 28 
animals were randomly selected to receive either a single intravenous injection of 3 × 106 
hUC-MSCs (sICH + hUC-MSC group; n = 13) or of the vehicle (sICH + Vehicle group; n = 15). 
These animals were followed up for a period of 22 days, during which 1 death occurred in 
the sICH + Vehicle group (within 24 h after the intravenous infusion of the vehicle) and no 
deaths were registered in the sICH + hUC-MSC group. Behavioral assessments were 
performed as described above in all animals. 1 animal from the mICH + hUC-MSC group 
was excluded from the study due to the wrong location of the hematoma on MRI. 
Biodistribution analysis 
The biodistribution of MSCs was evaluated in a separate cohort of animals. The cells were 
labeled with 99mTechnetium (99mTc) prior to the injection into animals from the following 
experimental groups: rats subjected to collagenase-induced mICH and sICH, sham-
operated rats, and naïve (unmanipulated) rats (n = 5-6 per group). Two hours after cell 
injection, whole-body scintigraphy was carried out in a gamma camera (General Electric 
Medical Systems) equipped with a low-energy, high-resolution collimator. A 15% energy 
window centered on the 140 keV photopeak of 99mTc was selected. Rats were euthanized 
as described above 24 h after 99mTc-labeled hUC-MSC transplantation. The cerebral 
hemispheres, heart, lungs, liver, kidneys, intestines, and spleen were removed and 
weighed. The radioactivity was measured using a gamma well counter (multi-crystal LB 
2111 gamma counter; Berthold Technologies), and the percentage of injected dose per 































































































































































































































































































The immunomodulatory activity of MSCs was evaluated in a separate cohort of animals (n 
= 6-7 per group). 48 h after sham operation or ICH induction (24 h after the intravenous 
injection of hUC-MSCs or of the vehicle) rats were deeply anesthetized via an 
intraperitoneal injection of a mixture of xylazine hydrochloride (15 mg/kg) and ketamine 
hydrochloride (100 mg/kg). Rats were then transcardially perfused with ice-cold 0.9% 
saline, and the ipsilateral brain hemispheres were collected and stored at -80 ºC. Tissues 
were homogenized in buffer (150 mM NaCl, 25 mM Tris, pH 7.4, 1% Triton X-100) 
containing a protease inhibitor cocktail (Promega). Total protein levels in the supernatants 
were measured using the PierceTM BCA protein assay kit (Thermo-Fisher Scientific). The 
Milliplex MAP Rat Cytokine/Chemokine Magnetic Bead Panel (RECYTMAG-65K; Millipore) 
was used to quantify the levels of monocyte chemoattractant protein-1 (MCP-1), 
interleukin (IL)-1β, IL-6 and IL-10 in the samples according to the manufacturer’s 
instructions. Assay plates were immediately read and analyzed on a Luminex® MAGPIX 
system (Millipore). All samples and standards were measured in duplicate. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 6.01 (GraphPad 
Software). Intergroup comparisons were performed by two-way analysis of variance 
(ANOVA) with repeated measures and Tukey's multiple comparison post hoc test (rotarod 
and elevated body swing tests), two-way ANOVA with Bonferroni's multiple comparison 
post hoc test (biodistribution analysis), one-way ANOVA with Bonferroni's post hoc test 
(Luminex® assay) or Student's t-test (MRI data analysis; after confirming the normality of 
the data using the D'Agostino-Pearson omnibus normality test), as indicated. The observed 
differences were considered significant when p < 0.05. 
Results 
Functional assessment 
We first investigated whether ICH would cause long-term behavioral deficits in young rats, 




























































































































































































































































































The rotarod performance test was used to evaluate motor coordination on days 3, 7, 14 
and 20 after surgery. Also, a baseline assessment was performed 2 days before surgery 
(Figure 1). First, using a model of mICH, we compared the latency to fall between sham-
operated animals (Sham), rats subjected to ICH and treated with the vehicle (mICH + 
Vehicle), and animals subjected to ICH and treated with hUC-MSCs (mICH + hUC-MSC). 
There were no statistically significant differences between the groups at any time point 
(Figure 2A). In contrast, animals subjected to sICH performed significantly worse than 
sham-operated animals on the rotarod test at the first post-surgery time point, regardless 
of the treatment (Figure 2A). Animals from both vehicle- and hUC-MSC-treated sICH 
groups exhibited performance improvement over time, although there was still a 
significant difference between the sICH + Vehicle and the sham-operated group on day 7 
(Figure 2A). In addition, animals from the sICH + hUC-MSC group had a slightly better 
performance than animals from the sICH + Vehicle group on day 20, although it did not 
reach statistical significance (Figure 2A). These results indicate that the mICH model did 
not result in long-term deficits in the rotarod test, whereas the sICH model induced at 
least a transient impairment that was not efficiently attenuated by hUC-MSCs. 
The elevated body swing test was performed on days 1, 8, 15 and 21 after surgery, as well 
as at baseline, for the measurement of asymmetrical motor behavior (Figure 1). This test 
revealed that, compared to the sham group, the mICH + Vehicle group had an increased 
percentage of right-side swings on day 8, although significant differences were not found 
at other time points (Figure 2B). In addition, the elevated body swing test revealed a 
biased swing activity to the right side in animals from both sICH groups, starting at the first 
day post-surgery and lasting over the entire surveillance period (Figure 2B). Statistically 
significant differences were observed when the percentage of right-side swings was 
compared between the sICH + Vehicle and the sham group, as well as between the sICH + 
hUC-MSC and the sham group, on days 1, 8, 15 and 21 after surgery (Figure 2B). No 
differences were observed between the sICH + Vehicle and the sICH + hUC-MSC group at 
any time point (Figure 2B). Taken together, these results suggest that the cell therapy 
might prevent a transient alteration in the elevated body swing test after mICH, although 




























































































































































































































































































groups. In addition, the elevated body swing test detected persistent impairments after 
sICH, which were not prevented by the hUC-MSC therapy. 
MRI 
Quantification of lesion volume on MRI images showed that the residual hematoma 
volume was significantly smaller in the mICH + hUC-MSC group than in the mICH + Vehicle 
group (Figure 3A-B). In order to evaluate hemispheric atrophy, we also quantified the ratio 
of the volumes of the ipsilaleral and contralateral hemispheres, but there was no 
difference between the two groups (Figure 3C). In contrast, the residual hematoma 
volume was not modified by the cell therapy after sICH (Figure 4A-B). We also quantified 
the ratio of the volumes of the ipsilaleral and contralateral hemispheres, but there was no 
difference between the two sICH groups (Figure 4C). 
Biodistribution of transplanted cells 
We also evaluated the biodistribution of 99mTc-labeled hUC-MSCs in different organs 
during the first 24 h after transplantation in naïve, sham, mICH and sICH animals (Figure 
5A). Whole-body nuclear imaging carried out 2 h after cell injection indicated activity in the 
lungs, liver, spleen and kidneys in all groups (Figure 5B). Gamma well counting at 24 h after 
hUC-MSC injection indicated higher uptake in the lungs, kidneys, spleen and liver, without 
significant differences between the experimental groups (Figure 5C). Although the activity 
in the brain was very low, we observed greater uptake in the ipsilateral (lesioned) 
hemisphere in animals subjected to sICH, in comparison to sham-operated rats and naïve 
animals (Figure 5D). 
Effects of hUC-MSCs on the expression of inflammatory mediators in the brain: 
To evaluate the potential immunomodulatory effects of hU-MSCs in the brain, we used a 
Luminex® assay to quantify the levels of two pro-inflammatory cytokines (IL-1β, and IL-6), 
an anti-inflammatory cytokine (IL-10) and a chemokine (MCP-1) in the ipsilateral 
hemisphere 24 h after hUC-MSCs transplantation in animals subjected to mICH or sICH. 
Sham-operated animals treated with an intravenous injection of the vehicle were used as 




























































































































































































































































































significant changes in the levels of these inflammatory mediators in the brain in 
comparison to the Sham group. Moreover, the cell therapy did not affect these results 
(Figure 6B). In contrast, we observed a statistically significant increase in the levels of MCP-
1 in the sICH + Vehicle group in comparison to the Sham group, which was not observed in 
the sICH + hUC-MSC group (Figure 6B). 
Discussion 
Here, we used MRI to investigate the potential therapeutic effects of the intravenous hUC-
MSCs infusion in two models of ICH. One of our main findings was that the residual 
hematoma volume was smaller in hUC-MSC-treated animals than in animals treated with 
the vehicle in the mICH model. In contrast, cell therapy did not change the residual 
hematoma volume after sICH. These results highlight the importance of studying the 
effects of novel therapies using more than one model, accounting for differences in the 
hematoma volume, one of the most important factors influencing outcomes in patients 
with ICH [37]. 
In order to understand the differential effects of hUC-MSCs in both conditions, it will first 
be necessary to investigate the mechanisms by which MSCs might contribute to 
hematoma resolution. MSCs have been shown to regulate the function of monocytes, 
microglia, and macrophages [38,39], cells that play fundamental roles in the processes of 
hematoma resolution and scar formation [10,40,41]. These immunomodulatory effects can 
be partly explained by the paracrine action of MSCs. Noh et al. showed that MSC-
conditioned media decreased the expression of pro-inflammatory cytokines by 
lipopolysaccharide-stimulated microglia, while increasing their phagocytic activity [42]. In 
addition, MSCs-derived extracellular vesicles have been shown to modulate the phenotype 
of microglia and macrophages in favor of an anti-inflammatory response [43,44], as well as 
to increase the expression of the scavenger receptor CD36 in macrophages [43], a 
molecule that mediates hematoma absorption following ICH [45]. MSCs could also 
attenuate the secondary phase of brain injury, which is attributed to the induction of 
oxidative stress and neuroinflammatory processes by blood products [46]. Several reports 




























































































































































































































































































[47,48], and that MSCs-derived extracellular vesicles can deliver antioxidant enzymes, 
including peroxiredoxins [49], catalase [48], and glutathione peroxidase 1 [50], to other 
cells. 
We have also employed two tests to evaluate whether the cell therapy would modify 
functional outcomes: the rotarod test and the elevated body swing test. None of them was 
capable of detecting sensorimotor deficits in mICH animals, except for a transient increase 
in the percentage of right side swings at day 8 post-ICH that was at least partially 
prevented by the cell therapy. Animals with a sICH exhibited enduring deficits in the 
elevated body swing test. However, these deficits were not ameliorated by hUC-MSCs. 
Also, the rotarod detected significant impairments in motor coordination after sICH, 
regardless of the treatment, although animals treated with hUC-MSCs had a slightly better 
performance (statistically not significant) at the last time point examined. These results are 
consistent with the findings of Kim et al. [23], who showed that animals subjected to ICH 
and treated with an intracerebroventricular injection of hUC-MSCs started to have a better 
performance in the rotarod test only at 4 weeks after transplantation, in comparison to 
untreated animals. Possible explanations for this delayed effect include the possibility that 
treated animals presented a greater capacity to learn compensatory strategies to perform 
the task [51], and/or that the presence of brain edema in the first days after ICH might 
have acted as a confounding factor [52]. These data indicate that the long-term 
assessment of the behavioral effects of cell therapies, as well as the utilization of 
additional behavioral tests, will need to be considered in future studies. Indeed, cognitive 
decline has been recently reported to occur in a model of ICH in mice [53], in contrast to 
what had been previously observed in rats [54,55]. 
Our study has limitations and our findings raise several questions that remain to be 
investigated. This was an exploratory study that only used male rats, but future larger 
studies are warranted to investigate whether there are sex-related differences related to 
hUC-MSCs-based therapies for ICH. The model of sICH employed in this study had a 
relatively high mortality rate. However, since almost all deaths occurred in the first 24 h 
after collagenase injection (i.e., before the infusion of hUC-MSCs), our experimental design 




























































































































































































































































































this regard, a recent study found that the intravenous injection of human placenta-derived 
MSCs 1 h after the injection of collagenase into the striatum of adult rats decreased the 
mortality rate from 50% to 8.3% at 24 h. Moreover, treated animals had smaller 
hematomas than animals that received the vehicle [56]. 
Only a single dose of 3 × 106 hUC-MSCs was tested in the present study. Although this 
number of transplanted cells corresponds to the average number of intravenously 
administered MSCs in previous studies [13,14], dose-escalation studies are still needed. 
Current data suggest that BM-MSCs improve neurological outcome in models of 
hemorrhagic and ischemic stroke but, as long as a minimum number of approximately 5 × 
105 cells is administered, there is no additional benefit from higher cell doses [14,57]. 
However, it is currently unknown whether the same is true for hUC-MSCs. A different 
behavior of hUC-MSCs cannot be excluded bona fide given, for instance, the observed 
differences in the expression of genes related to immunomodulatory and proregenerative 
functions [16,17]. 
We decided to use freshly thawed cells in this study considering that this is a more likely 
scenario in future clinical trials, especially if the cells are going to be delivered at acute 
time points. Freeze-thawing has been shown to decrease the responsiveness of MSCs to 
interferon-γ and to compromise their immunosuppressive capacity in vitro [58,59], but 
Hoogduijn et al. showed that MSCs exhibited limited gene expression changes after 
thawing [60]. Freshly thawed MSCs and cells that have been continuously cultured induced 
a similar pattern of expression of cytokines and chemokines in the lungs of healthy mice 
[60], and were equally effective in improving several parameters in a model of allergic 
airway inflammation [61]. Moreover, a recent meta-analysis of preclinical studies that 
investigated the effects of BM-MSCs in models of ischemic stroke showed that frozen cells 
were equally or even more effective than fresh cells in improving functional outcomes 
[57].  
Finally, we showed that the percentage of transplanted cells that reached the brain 24 h 
after injection was very low. These findings are consistent with the hypothesis that MSCs 




























































































































































































































































































of by replacing lost brain cells [62]. It is assumed that these effects include the modulation 
of local and systemic immune responses [63]. Here, we observed an increase in the 
expression of MCP-1 in the brain in the sICH + Vehicle group in comparison to the Sham 
group, which was not observed when the sICH + hUC-MSC group was compared to the 
Sham group, suggesting an immunomodulatory effect of the cell therapy. It was not 
possible to assess the potential immunomodulatory effects of hUC-MSCs in the model of 
mICH since there were no statistically significant differences between the mICH + Vehicle 
and the Sham groups, probably because of the late time point chosen (48 h after ICH). 
Regarding the systemic actions of MSCs, Badner and colleagues, for example, have 
demonstrated that some of the beneficial effects of hUC-MSCs in a model of traumatic 
spinal cord injury were not observed in splenectomized mice [64]. Other studies have 
suggested that the interaction of MSCs with other cells during the pulmonary passage 
might be an important step for the protection of the blood-brain barrier after a traumatic 
brain injury [65], or for the regulation of the inflammatory response and the reduction of 
infarct size in a model of myocardial infarction [66]. Another possibility is that circulating 
MSCs or MSCs that are trapped in tissue capillaries could release extracellular vesicles into 
the blood stream. These extracellular vesicles could then act in different organs, including 
the brain. Indeed, MSCs-derived extracellular vesicles have been shown to have protective 
effects in models of ICH [67,68]. A previous study, however, found no differences when 
comparing the intravenous and the intracerebral routes for the delivery of human 
umbilical cord-derived mesenchymal stromal cells in a model of ICH [25]. Nevertheless, it 
would be interesting to compare the effects of different cell deliveries routes and 
bioengineering approaches that could potentially increase the number of MSCs that reach 
the brain to the effects of the intravenous route that was used here.  
In conclusion, the results presented here indicate that the efficacy of intravenously infused 
hUC-MSCs in reducing the lesion size following ICH in young-adult rats might depend on 
the volume of the initial hematoma, and that optimization of hUC-MSC-based therapies 
are therefore necessary. The data on the biodistribution of transplanted cells suggest that 




























































































































































































































































































consequently, for the improvement of cell therapies, relies on the investigation of the role 
of local versus systemic effects of hUC-MSCs. 
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Figure 1 – Experimental design. EBS: elevated body swing test; hUC-MSC: human umbilical 































































































































































































































































































Figure 2 – Functional assessment in models of moderate and severe intracerebral 
hemorrhage. (A) Latency to fall in the Rotarod performance test at different time points 
from surgery. (B) Percentage of right turns in the elevated body swing test at different 
time points from surgery. hUC-MSC: human umbilical cord mesenchymal stromal cells; 
mICH: moderate intracerebral hemorrhage; sICH: severe intracerebral hemorrhage. ¥ 
comparison between Sham and mICH + Vehicle groups, * comparisons between Sham and 
sICH + Vehicle groups, # comparisons between Sham and sICH + hUC-MSC groups; *, or # ρ 
< 0.05, ## or ¥¥ ρ < 0.01, ***, or ### ρ < 0.001; Two-way ANOVA with repeated measures, 
Tukey's post-hoc test. Data shown in the graphs are means ± S.E.M. n = 10 animals in the 
Sham group, 9 animals in the mICH + Vehicle group (8 for the rotarod test), 10 animals in 
the mICH + hUC-MSC group (8 for the rotarod test), 14 animals in the sICH + Vehicle group 






























































































































































































































































































Figure 3 - Animals treated with human umbilical cord-derived mesenchymal stromal cells 
had a smaller hematoma volume than vehicle-treated animals after a moderate 
intracerebral hemorrhage. (A) Representative T1-weighted images obtained with a 3D 
sequence in a 7 Tesla magnetic resonance imaging scanner 22 days after the induction of a 
moderate intracerebral hemorrhage. Animals were treated with human umbilical cord-
derived mesenchymal stromal cells (mICH + hUC-MSC) or with the vehicle (mICH + Vehicle) 
24 h after the injury. (B and C) Graphs showing the quantification of the residual 
hematoma volume (B) and the ratio between the volumes of the ipsilateral and 
contralateral hemispheres (C), respectively. Data shown in the graphs are means ± S.E.M. * 
p < 0.05; Student's t-test. n = 9 rats in the mICH + Vehicle group and 10 animals in the 






























































































































































































































































































Figure 4 - Human umbilical cord-derived mesenchymal stromal cells did not modify the 
residual hematoma volume after a severe intracerebral hemorrhage. (A) Representative 
T1-weighted images obtained with a 3D sequence in a 2 Tesla magnetic resonance imaging 
scanner 22 days after the induction of a severe intracerebral hemorrhage. Animals were 
treated with human umbilical cord-derived mesenchymal stromal cells (sICH + hUC-MSC) 
or with the vehicle (sICH + Vehicle) 24 h after the injury. (B and C) Graphs showing the 
quantification of the residual hematoma volume (B) and the ratio between the volumes of 
the ipsilateral and contralateral hemispheres (C), respectively. Data shown in the graphs 
are means ± S.E.M. Student's t-test. n = 14 rats in the sICH + Vehicle group and 12 animals 






























































































































































































































































































Figure 5 – Biodistribution of transplanted cells. (A) Experimental design. (B) 
Representative whole-body images demonstrating the biodistribution of 99mTechnetium-
labeled human umbilical cord-derived mesenchymal stromal cells (99mTc-hUC-MSC) 2 h 
after a single intravenous infusion in rats subjected to collagenase-induced moderate and 
severe intracerebral hemorrhage (mICH and sICH, respectively), sham-operated animals 
(Sham), and naïve rats. (C, D) Graphs showing the biodistribution of 99mTc-hUC-MSC 24 h 
after a single intravenous infusion in rats from the different experimental groups. Tracer 
activity is expressed as the percentage of injected dose per gram of tissue (% dose / g). 
Data on the distribution of injected cells in the brain is shown in detail in (D). Data shown 
in the graphs are means ± S.E.M. n = 5 or 6 (sICH group) animals per group. Two-way 





























































































































































































































































































Figure 6 – Effects of human umbilical cord-derived mesenchymal stromal cells on the 
expression of inflammatory mediators in the brain. (A) Experimental design. Animals 
were subjected to collagenase-induced moderate or severe intracerebral hemorrhage 
(mICH and sICH, respectively) and then were treated with human umbilical cord-derived 
mesenchymal stromal cells (hUC-MSC) or with the vehicle 24 h after the injury. Sham-
operated animals treated with an intravenous injection of the vehicle (Sham) were used as 
controls. A Luminex® assay was used to quantify the levels of interleukin (IL)-1β, IL-6, IL-10, 
and monocyte chemoattractant protein 1 (MCP-1) in the brain (ipsilateral hemisphere) 24 
h after the intravenous injection of the cells or of the vehicle. (B) Graphs show individual 
values and means ± S.E.M. n = 6 (mICH + Vehicle) or 7 animals per group. One-way ANOVA, 
Bonferroni's post-hoc test. ** p < 0.01. 
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